-
Product Insights
Likelihood of Approval Analysis for Cerebrovascular Disease
Overview How likely is it that the drugs in Cerebrovascular Disease will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cerebrovascular Disease Overview Cerebrovascular disease refers to a group of conditions that...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibudilast in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibudilast in Amyotrophic Lateral Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibudilast in Amyotrophic Lateral Sclerosis Drug Details: Ibudilast (Ketas) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibudilast in Chemotherapy Induced Peripheral Neuropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibudilast in Chemotherapy Induced Peripheral Neuropathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibudilast in Chemotherapy Induced Peripheral Neuropathy Drug Details: Ibudilast (Ketas)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibudilast in Alcohol Dependence
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibudilast in Alcohol Dependence report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibudilast in Alcohol Dependence Drug Details: Ibudilast (Ketas) is an anti-inflammatory and...
-
Product Insights
Cerebral Infarction (Brain Infarction) – Drugs In Development, 2023
Global Markets Direct’s, ‘Cerebral Infarction (Brain Infarction) - Drugs In Development, 2023’, provides an overview of the Cerebral Infarction (Brain Infarction) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cerebral Infarction (Brain Infarction), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Ischemic Stroke – Drugs In Development, 2023
Global Markets Direct’s, ‘Ischemic Stroke - Drugs In Development, 2023’, provides an overview of the Ischemic Stroke pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Acute Ischemic Stroke – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Ischemic Stroke - Drugs In Development, 2023’, provides an overview of the Acute Ischemic Stroke pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Sector Analysis
Acute Ischemic Stroke (AIS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Acute Ischemic Stroke Competitive Analysis Report Overview AIS is a medical emergency caused by decreased blood flow to the brain, which results in damage to brain cells. It occurs when a blood vessel in the brain is blocked by a clot or mass, impeding blood flow to brain cells. The primary cause of ischemic stroke is atherosclerosis, the accumulation of fatty deposits (plaque) on vessel walls. These deposits can cause two types of obstruction, including cerebral thrombosis and cerebral embolism. Key Mechanisms...